JP6325573B2 - Btkキナーゼ抑制剤としての2,3−ジヒドロ−イソインドール−1−オン誘導体及びこれを含む薬学的組成物 - Google Patents

Btkキナーゼ抑制剤としての2,3−ジヒドロ−イソインドール−1−オン誘導体及びこれを含む薬学的組成物 Download PDF

Info

Publication number
JP6325573B2
JP6325573B2 JP2015550315A JP2015550315A JP6325573B2 JP 6325573 B2 JP6325573 B2 JP 6325573B2 JP 2015550315 A JP2015550315 A JP 2015550315A JP 2015550315 A JP2015550315 A JP 2015550315A JP 6325573 B2 JP6325573 B2 JP 6325573B2
Authority
JP
Japan
Prior art keywords
phenyl
methyl
fluoro
imidazol
urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015550315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016504351A5 (enExample
JP2016504351A (ja
Inventor
ホン,ヨン・レ
ナ,ジョン・ユン
ミン,イム・ソク
チャ,ヒュン・ジュ
クウォン,ソル・キ
ロ,ショング
チョウ,ジョン・ミュン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CrystalGenomics Inc
Original Assignee
CrystalGenomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CrystalGenomics Inc filed Critical CrystalGenomics Inc
Publication of JP2016504351A publication Critical patent/JP2016504351A/ja
Publication of JP2016504351A5 publication Critical patent/JP2016504351A5/ja
Application granted granted Critical
Publication of JP6325573B2 publication Critical patent/JP6325573B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015550315A 2012-12-28 2013-12-26 Btkキナーゼ抑制剤としての2,3−ジヒドロ−イソインドール−1−オン誘導体及びこれを含む薬学的組成物 Active JP6325573B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261746980P 2012-12-28 2012-12-28
US61/746,980 2012-12-28
PCT/KR2013/012204 WO2014104757A1 (ko) 2012-12-28 2013-12-26 Btk 키나아제 억제제로서의 2,3-디하이드로-이소인돌-1-온 유도체 및 이를 함유하는 약학적 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018076877A Division JP6596537B2 (ja) 2012-12-28 2018-04-12 Btkキナーゼ抑制剤としての2,3−ジヒドロ−イソインドール−1−オン誘導体及びこれを含む薬学的組成物

Publications (3)

Publication Number Publication Date
JP2016504351A JP2016504351A (ja) 2016-02-12
JP2016504351A5 JP2016504351A5 (enExample) 2017-02-16
JP6325573B2 true JP6325573B2 (ja) 2018-05-16

Family

ID=51021712

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015550315A Active JP6325573B2 (ja) 2012-12-28 2013-12-26 Btkキナーゼ抑制剤としての2,3−ジヒドロ−イソインドール−1−オン誘導体及びこれを含む薬学的組成物
JP2018076877A Active JP6596537B2 (ja) 2012-12-28 2018-04-12 Btkキナーゼ抑制剤としての2,3−ジヒドロ−イソインドール−1−オン誘導体及びこれを含む薬学的組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018076877A Active JP6596537B2 (ja) 2012-12-28 2018-04-12 Btkキナーゼ抑制剤としての2,3−ジヒドロ−イソインドール−1−オン誘導体及びこれを含む薬学的組成物

Country Status (15)

Country Link
US (4) US9758508B2 (enExample)
EP (2) EP2940014B1 (enExample)
JP (2) JP6325573B2 (enExample)
KR (1) KR102009163B1 (enExample)
CN (1) CN104995184B (enExample)
AU (3) AU2013371146C1 (enExample)
BR (1) BR112015015477B1 (enExample)
CA (1) CA2896711C (enExample)
DK (1) DK2940014T3 (enExample)
ES (2) ES2696700T3 (enExample)
MX (2) MX386542B (enExample)
PL (1) PL2940014T3 (enExample)
PT (1) PT2940014T (enExample)
RU (2) RU2018138028A (enExample)
WO (1) WO2014104757A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018109069A (ja) * 2012-12-28 2018-07-12 クリスタルジェノミクス・インコーポレイテッドCrystalgenomics, Inc. Btkキナーゼ抑制剤としての2,3−ジヒドロ−イソインドール−1−オン誘導体及びこれを含む薬学的組成物

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
US11590167B2 (en) 2016-12-03 2023-02-28 Juno Therapeutic, Inc. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド RETキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピラジン化合物
KR20190128646A (ko) * 2017-02-21 2019-11-18 압토스 바이오사이언시스 인코포레이티드 혈액 종양 환자들의 치료 방법
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
US20200171001A1 (en) * 2018-11-30 2020-06-04 Aptose Biosciences Inc. Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
US20240091226A1 (en) * 2021-01-05 2024-03-21 Sumitomo Pharma Oncology, Inc. Forms and Formulations Of A Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitor
CN117295737A (zh) * 2021-03-05 2023-12-26 林伯士萨顿公司 Hpk1拮抗剂和其用途
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1379511B1 (en) * 2001-04-12 2005-07-20 F. Hoffmann-La Roche Ag DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II
WO2004108672A1 (en) * 2003-06-02 2004-12-16 Abbott Laboratories Isoindolin-1-one compounds as kinase inhibitors
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
KR20080011199A (ko) * 2005-04-19 2008-01-31 교와 핫꼬 고교 가부시끼가이샤 질소 함유 복소환 화합물
US20070161648A1 (en) * 2005-10-14 2007-07-12 Hughes Terry V Substituted dihydro-isoindolones useful in treating kinase disorders
WO2007107469A1 (en) * 2006-03-20 2007-09-27 F. Hoffmann-La Roche Ag Methods of inhibiting btk and syk protein kinases
JPWO2008047831A1 (ja) * 2006-10-17 2010-02-25 協和発酵キリン株式会社 Jak阻害剤
JP5587193B2 (ja) * 2007-10-23 2014-09-10 エフ.ホフマン−ラ ロシュ アーゲー 新規なキナーゼ阻害剤
WO2012014017A1 (en) 2010-07-30 2012-02-02 Poly Medicure Limited Catheter introducer
WO2012047017A2 (ko) * 2010-10-05 2012-04-12 크리스탈지노믹스(주) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물
DK2940014T3 (en) 2012-12-28 2018-12-10 Crystalgenomics Inc 2,3-DIHYDRO-ISOINDOL-1-ON DERIVATIVE AS BTK KINase INHIBITORS AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018109069A (ja) * 2012-12-28 2018-07-12 クリスタルジェノミクス・インコーポレイテッドCrystalgenomics, Inc. Btkキナーゼ抑制剤としての2,3−ジヒドロ−イソインドール−1−オン誘導体及びこれを含む薬学的組成物

Also Published As

Publication number Publication date
KR20160058720A (ko) 2016-05-25
US20170362205A1 (en) 2017-12-21
JP6596537B2 (ja) 2019-10-23
CN104995184A (zh) 2015-10-21
AU2018214134B2 (en) 2020-03-12
CN104995184B (zh) 2018-01-02
EP2940014B1 (en) 2018-09-26
HK1259355A1 (en) 2019-11-29
KR102009163B1 (ko) 2019-08-09
ES2696700T3 (es) 2019-01-17
JP2016504351A (ja) 2016-02-12
BR112015015477A2 (pt) 2017-07-11
BR112015015477B1 (pt) 2022-07-12
PL2940014T3 (pl) 2019-03-29
US20220380346A1 (en) 2022-12-01
RU2018138028A (ru) 2019-03-21
AU2013371146C1 (en) 2019-01-17
US10604508B2 (en) 2020-03-31
RU2015124381A (ru) 2017-02-01
PT2940014T (pt) 2018-11-28
DK2940014T3 (en) 2018-12-10
AU2020201431A1 (en) 2020-03-19
EP3428161A1 (en) 2019-01-16
EP3428161B1 (en) 2022-09-07
AU2018214134A1 (en) 2018-08-30
MX2021011563A (es) 2022-10-10
WO2014104757A1 (ko) 2014-07-03
ES2929906T3 (es) 2022-12-02
US20150336934A1 (en) 2015-11-26
AU2013371146A1 (en) 2015-07-16
EP2940014A1 (en) 2015-11-04
RU2671847C2 (ru) 2018-11-07
US9758508B2 (en) 2017-09-12
CA2896711A1 (en) 2014-07-03
US11230539B2 (en) 2022-01-25
MX386542B (es) 2025-03-18
JP2018109069A (ja) 2018-07-12
CA2896711C (en) 2019-12-31
EP2940014A4 (en) 2016-06-22
AU2020201431B2 (en) 2021-07-22
MX2015008396A (es) 2016-04-15
AU2013371146B2 (en) 2018-05-10
US20210009565A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
JP6596537B2 (ja) Btkキナーゼ抑制剤としての2,3−ジヒドロ−イソインドール−1−オン誘導体及びこれを含む薬学的組成物
JP2019503395A (ja) ピロロピリミジン5員環アザ環状誘導体およびその利用
JP6928986B2 (ja) キナーゼ活性を阻害するためのインダゾール系化合物、その組成物および使用
WO2019096112A1 (zh) 一种取代的苯并咪唑化合物及包含该化合物的组合物
CN105228609A (zh) 新的转录因子调节剂
CN115353489A (zh) 一种氘代酰胺类衍生物及其应用
HK1259355B (en) 2,3-dihydro-isoindole-1-one derivative as btk kinase suppressant, and pharmaceutical composition including same
CN112250672B (zh) 一种核苷碱基衍生物及其制备方法和应用
JP2021534180A (ja) 置換4−アミノ−1H−イミダゾ[4,5−c]キノリン化合物およびその製造の改良法
RU2812575C2 (ru) Ингибитор jak и способ его получения
TW202430505A (zh) 萘醯胺類化合物、其製備方法及其應用
JPH0688996B2 (ja) 5−フルオロウラシル誘導体
JP2025502475A (ja) ジイミド誘導体、その調製方法、及び使用
WO2024000615A1 (zh) 一种酪氨酸蛋白激酶抑制剂及其用途
JP2023531097A (ja) テトラヒドロイソキノリン類誘導体の塩、その製造方法及びその医薬学的応用
JP2001114678A (ja) チロシン脱リン酸化酵素阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180313

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180412

R150 Certificate of patent or registration of utility model

Ref document number: 6325573

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250